United Kingdom RNA Interference (Rnai) Drug Delivery Market Forecast 2024-2032

The United Kingdom RNA interference (RNAi) drug delivery market is expected to develop at a CAGR of 23.08% over the forecast period of 2024-2032. It is set to reach a revenue of $20807.84 million by 2032.

MARKET INSIGHTS

The United Kingdom RNA interference (RNAi) drug delivery market is witnessing a notable surge in demand, primarily driven by the increasing adoption of RNA-based therapeutics. This demand is fueled by the pressing need for innovative solutions to address the rising burden of chronic diseases across the population. RNAi technology offers promising avenues for targeted and precise drug delivery, aligning with the growing emphasis on personalized medicine and therapeutic efficacy.

Amidst this growth trajectory, investments in RNA-based research are escalating, further amplifying market dynamics. These investments are fostering technological advancements in RNAi delivery systems and aiding the development of novel RNA-based therapies. This influx of research funding is instrumental in expanding the scope and capabilities of RNAi drug delivery, paving the way for more efficient and effective treatment options.

However, alongside these opportunities, the RNA interference (RNAi) drug delivery market in the UK faces significant challenges. One key challenge lies in the inherent complexity of RNAi technology. Delivering RNA-based therapeutics requires sophisticated delivery mechanisms that can navigate biological barriers and ensure targeted delivery to the intended cells or tissues. Overcoming these technical complexities is crucial for realizing the full potential of RNAi in clinical applications.

Moreover, regulatory hurdles pose another barrier to market growth. The stringent regulatory landscape governing RNA-based therapies necessitates comprehensive safety and efficacy assessments, adding time and costs to the drug development and approval process. Addressing these regulatory challenges requires collaborative efforts between industry stakeholders, regulatory authorities, and research institutions to streamline processes and accelerate market access for RNAi-based treatments.

In navigating these challenges, industry players are focusing on innovation and collaboration to drive market expansion. Partnerships between pharmaceutical companies, research institutions, and technology providers are fostering the development of advanced RNAi delivery platforms. These collaborations are accelerating the translation of research findings into clinical applications, driving innovation in RNA-based therapeutics and enhancing patient care outcomes. Collaborative initiatives in the market are further essential for overcoming barriers and enhancing market competitiveness. They play a critical role in delivering transformative RNA-based therapies to patients in need, ultimately improving healthcare outcomes and addressing unmet medical needs.

SEGMENTATION ANALYSIS

The United Kingdom RNA interference (RNAi) drug delivery market segmentation incorporates the market by application and technology. The application segment is further divided into oncology, infectious disease, neurology, cardiology, metabolic disorders, ophthalmology, urology, and other applications. RNAi technology has shown potential in combating viral infections by targeting specific viral RNA sequences, thereby inhibiting viral replication. This approach has implications for addressing emerging infectious diseases and improving the efficacy of antiviral therapies. With ongoing research and development efforts, RNAi-based treatments for infectious diseases are poised to contribute significantly to the healthcare landscape, especially in response to global health challenges.

Cardiology is also emerging as a noteworthy application segment in the market. RNAi technology offers potential solutions for managing cardiovascular diseases by targeting genes involved in cardiac function and pathology. Through targeted interventions, RNAi-based treatments aim to improve heart health, manage risk factors, and reduce the incidence of cardiovascular events. This sub-segment's growth is pushed by the rising burden of cardiovascular disorders and the need for advanced therapeutic approaches to address cardiovascular health challenges effectively.

Metabolic disorders represent a significant area of focus within the RNAi drug delivery industry in the United Kingdom. By targeting genes associated with metabolic pathways, RNAi-based therapies offer potential solutions for managing conditions such as diabetes, obesity, and metabolic syndromes. These therapies aim to regulate metabolic processes, improve insulin sensitivity, and address underlying metabolic dysfunctions. This sub-segment's growth is propelled by the growing demand for innovative treatments that can effectively manage these complex health conditions.

COMPETITIVE ANALYSIS

Leading players operating in the United Kingdom RNA interference (RNAi) drug delivery market include Ionis Pharmaceuticals Inc, Silence Therapeutics PLC, Sirnaomics Inc, etc.

Silence Therapeutics PLC is a biotechnology company specializing in utilizing short-interfering ribonucleic acid (siRNA) to suppress specific protein expression through gene silencing for disease management. The firm focuses on three primary therapeutic areas: cardiovasular disease, hematology, and rare diseases. Using N-acetylgalactosamine (GalNAc) for receptor-mediated targeting, Silence Therapeutics improves RNAi molecule delivery to liver cells via its mRNAi GOLD platform. The company collaborates with AstraZeneca, Mallinckrodt, and Hansoh, each targeting distinct disease areas, providing initial capital and generating milestone revenues. Headquartered in the United Kingdom, Silence Therapeutics PLC is at the forefront of innovative RNA-based therapies.

Product Code: 88628

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.6. MAJOR MARKET FINDINGS
- 2.6.1. CARDIOLOGY IS THE FASTEST-GROWING RNAI DRUG DELIVERY APPLICATION
- 2.6.2. NANOPARTICLE DRUG DELIVERY IS THE MAJORLY PREFERRED RNAI DRUG DELIVERY TECHNOLOGY

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INCREASING DEMAND FOR RNA-BASED THERAPEUTICS TO STIMULATE MARKET GROWTH
- 3.1.2. RISING PREVALENCE OF CHRONIC DISEASES FOSTERS MARKET DEMAND
- 3.1.3. GROWING INVESTMENT IN RNA-BASED RESEARCH TO ESCALATE THE MARKET GROWTH
3.2. KEY RESTRAINTS
- 3.2.1. THE COMPLEXITY OF RNAI TECHNOLOGY IS PREDICTED TO HINDER MARKET DEMAND
- 3.2.2. REGULATORY CHALLENGES ARE EXPECTED TO FURTHER COMPLICATE MARKET GROWTH

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. RNAI DRUGS HAVE APPLICATIONS IN CANCER TREATMENT
- 4.1.2. INFECTIOUS DISEASES ARE LEADING TO INCREASED TRACTION IN RNAI DRUGS
- 4.1.3. VENTURE FUNDING FOR RNAI DRUGS HAS INCREASED SUBSTANTIALLY
4.2. PORTER'S FIVE FORCES ANALYSIS
- 4.2.1. BUYERS POWER
- 4.2.2. SUPPLIERS POWER
- 4.2.3. SUBSTITUTION
- 4.2.4. NEW ENTRANTS
- 4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
- 4.3.1. GROWTH PROSPECT MAPPING FOR UNITED KINGDOM
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
- 4.6.1. PRIMARY ACTIVITIES
  - 4.6.1.1. RESEARCH AND DEVELOPMENT (R&D)
  - 4.6.1.2. MANUFACTURING
  - 4.6.1.3. LOGISTICS AND DISTRIBUTION
  - 4.6.1.4. MARKETING AND SALES
  - 4.6.1.5. AFTER-SALES SERVICE
- 4.6.2. SUPPORT ACTIVITIES
  - 4.6.2.1. PROCUREMENT
  - 4.6.2.2. TECHNOLOGY DEVELOPMENT
  - 4.6.2.3. HUMAN RESOURCE MANAGEMENT
  - 4.6.2.4. FIRM INFRASTRUCTURE
  - 4.6.2.5. REGULATORY AFFAIRS AND COMPLIANCE
4.7. KEY BUYING CRITERIA
- 4.7.1. EFFICACY AND SAFETY
- 4.7.2. MECHANISM OF ACTION AND TARGET SPECIFICITY
- 4.7.3. DELIVERY SYSTEM AND ADMINISTRATION ROUTE
- 4.7.4. COMPETITIVE ADVANTAGE AND DIFFERENTIATION
- 4.7.5. REGULATORY APPROVAL AND COMPLIANCE
- 4.7.6. COST AND REIMBURSEMENT
- 4.7.7. INTELLECTUAL PROPERTY AND EXCLUSIVITY
- 4.7.8. MANUFACTURING CAPABILITIES AND SUPPLY CHAIN
- 4.7.9. COMPANY REPUTATION AND EXPERIENCE

5. MARKET BY APPLICATION

5.1. ONCOLOGY
- 5.1.1. MARKET FORECAST FIGURE
- 5.1.2. SEGMENT ANALYSIS
5.2. INFECTIOUS DISEASE
- 5.2.1. MARKET FORECAST FIGURE
- 5.2.2. SEGMENT ANALYSIS
5.3. NEUROLOGY
- 5.3.1. MARKET FORECAST FIGURE
- 5.3.2. SEGMENT ANALYSIS
5.4. CARDIOLOGY
- 5.4.1. MARKET FORECAST FIGURE
- 5.4.2. SEGMENT ANALYSIS
5.5. METABOLIC DISORDERS
- 5.5.1. MARKET FORECAST FIGURE
- 5.5.2. SEGMENT ANALYSIS
5.6. OPHTHALMOLOGY
- 5.6.1. MARKET FORECAST FIGURE
- 5.6.2. SEGMENT ANALYSIS
5.7. UROLOGY
- 5.7.1. MARKET FORECAST FIGURE
- 5.7.2. SEGMENT ANALYSIS
5.8. OTHER APPLICATIONS
- 5.8.1. MARKET FORECAST FIGURE
- 5.8.2. SEGMENT ANALYSIS

6. MARKET BY TECHNOLOGY

6.1. NANOPARTICLE DRUG DELIVERY
- 6.1.1. MARKET FORECAST FIGURE
- 6.1.2. SEGMENT ANALYSIS
6.2. PULMONARY DRUG DELIVERY
- 6.2.1. MARKET FORECAST FIGURE
- 6.2.2. SEGMENT ANALYSIS
6.3. NUCLEIC ACID DRUG DELIVERY
- 6.3.1. MARKET FORECAST FIGURE
- 6.3.2. SEGMENT ANALYSIS
6.4. APTAMER DRUG DELIVERY
- 6.4.1. MARKET FORECAST FIGURE
- 6.4.2. SEGMENT ANALYSIS

7. COMPETITIVE LANDSCAPE

7.1. KEY MARKET STRATEGIES
- 7.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
- 7.1.2. PARTNERSHIPS & AGREEMENTS
7.2. COMPANY PROFILES
- 7.2.1. ALNYLAM PHARMACEUTICALS INC
  - 7.2.1.1. COMPANY OVERVIEW
  - 7.2.1.2. PRODUCT PORTFOLIO
  - 7.2.1.3. STRENGTHS & CHALLENGES
- 7.2.2. ARBUTUS BIOPHARMA CORP
  - 7.2.2.1. COMPANY OVERVIEW
  - 7.2.2.2. PRODUCT PORTFOLIO
  - 7.2.2.3. STRENGTHS & CHALLENGES
- 7.2.3. IONIS PHARMACEUTICALS INC
  - 7.2.3.1. COMPANY OVERVIEW
  - 7.2.3.2. PRODUCT PORTFOLIO
  - 7.2.3.3. STRENGTHS & CHALLENGES
- 7.2.4. SIRNAOMICS INC
  - 7.2.4.1. COMPANY OVERVIEW
  - 7.2.4.2. PRODUCT PORTFOLIO
  - 7.2.4.3. STRENGTHS & CHALLENGES
- 7.2.5. SILENCE THERAPEUTICS PLC
  - 7.2.5.1. COMPANY OVERVIEW
  - 7.2.5.2. PRODUCT PORTFOLIO
  - 7.2.5.3. STRENGTHS & CHALLENGES

Product Code: 88628

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - RNA INTERFERENCE (RNAI) DRUG DELIVERY
TABLE 2: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 7: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR UNITED KINGDOM
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023
FIGURE 9: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY ONCOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 10: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY INFECTIOUS DISEASE, 2024-2032 (IN $ MILLION)
FIGURE 11: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NEUROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 12: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY CARDIOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 13: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY METABOLIC DISORDERS, 2024-2032 (IN $ MILLION)
FIGURE 14: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY OPHTHALMOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 15: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY UROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 16: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY OTHER APPLICATIONS, 2024-2032 (IN $ MILLION)
FIGURE 17: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2023
FIGURE 18: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NANOPARTICLE DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 19: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 20: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NUCLEIC ACID DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 21: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APTAMER DRUG DELIVERY, 2024-2032 (IN $ MILLION)

United Kingdom RNA Interference (Rnai) Drug Delivery Market Forecast 2024-2032

Description

Table of Contents

List of Tables

KEY FINDINGS